Related Experiment Video
Updated: Jul 16, 2026

09:02
Cortical Bone Assessment Using Ultrasonic Guided Waves: A Reproducibility Study in a Healthy Population
Published on: January 31, 2025
Routine Laboratory Markers as Incremental Predictors Beyond OSTA for Dual-Energy X-Ray Absorptiometry-Defined
Ömer Faruk Öz1, Can Dinç1, Özge Berfin Babayiğit1
1Department of Obstetrics and Gynecology, Akdeniz University Faculty of Medicine, 07070 Antalya, Türkiye.
Diagnostics (Basel, Switzerland)
|July 15, 2026
Summary
Routine lab tests offer limited additional value for predicting osteoporosis in postmenopausal women beyond the Osteoporosis Self-Assessment Tool for Asians (OSTA). These markers are not a substitute for DXA scans or fracture risk assessment.
Area of Science:
- Endocrinology
- Geriatrics
- Clinical Chemistry
Background:
- Osteoporosis diagnosis relies on bone mineral density (BMD) via DXA scans.
- The Osteoporosis Self-Assessment Tool for Asians (OSTA) is a common screening tool.
- The added value of routine laboratory markers for osteoporosis risk stratification is unclear.
Purpose of the Study:
- To assess if serum uric acid, albumin, alkaline phosphatase (ALP), and inflammatory indices improve osteoporosis prediction beyond OSTA in postmenopausal women.
- To evaluate the incremental predictive value of routine lab tests in a referral setting.
Main Methods:
- Retrospective cross-sectional study of 3504 postmenopausal women referred for DXA.
- Osteoporosis defined by DXA T-score ≤ -2.5.
- Multivariable logistic regression and 10-fold cross-validation were used.
Main Results:
- Osteoporosis was present in 47.4% of women.
- OSTA alone had an AUC of 0.679.
- Adding uric acid, albumin, and ALP modestly increased AUC to 0.695, with minor improvements in calibration and Brier score.
Conclusions:
- Routine laboratory variables offer only modest incremental value for osteoporosis prediction beyond OSTA.
- This model is an exploratory tool for referral pathway prioritization, not a screening or diagnostic surrogate for DXA.